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The current prescription of clozapine in psychotic women of reproductive age makes it
crucial to understand its pharmacokinetics during pregnancy and lactation as well as its
risk profile for neonatal outcome. The aim of this case series was to provide new evidence
on the pharmacokinetic features of clozapine that determine its passage through the
placenta and amniotic fluid, as well as the neonatal clozapine elimination half-life (t1/2).
This case series demonstrates for the first time that clozapinemight show partial placental
passage similar to other atypical antipsychotics. Clozapine levels decreased during
the first few days in nursing infants. The half-life of clozapine in neonates was slightly
higher than previously estimated. Clozapine use in pregnancy may be associated with
diabetes mellitus, especially if there is a family history of this disease. Although no acute
toxicological effects were observed in the intrauterine exposed newborn, close follow-up
of pregnancy is recommended. However, these results must be taken with caution being
a case series with small sample size
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INTRODUCTION
Clozapine is a second-generation antipsychotic agent, chemically a di-benzodiazepine, that is
approved for treatment-resistant schizophrenia and risk reduction of recurrent suicidal behavior in
schizophrenia or schizoaffective disorder. It is also used off-label to reduce craving in patients with
substance use disorder (SUD) comorbidity (Hasan et al., 2015). Clozapine acts as an antagonist
of serotonin 5HT2, dopamine D2, α1-adrenergic, muscarinic and H1 histaminic receptors and
it induces relatively few extrapyramidal effects (Stahl, 2017). Unlike some first- and second-
generation antipsychotics, it does not cause sustained increases in serum prolactin levels and does
not affect other hormonal levels sufficiently to inhibit fertility (Haddad and Wieck, 2004).
A recent systematic review of the safety of clozapine during pregnancy and lactation found
very limited data on the topic (Mehta and Van Lieshout, 2017). In pregnant women, clozapine
appears to be associated with an increased risk of gestational diabetes mellitus compared to
mothers not taking any antipsychotic (Bodén et al., 2012), as also observed in several case reports
Imaz et al. Clozapine, Pregnancy, and Lactation
(Waldman and Safferman, 1993; Dickson and Hogg, 1998;
Nguyen and Lalonde, 2003; Karakula et al., 2004). Regarding the
consequences for fetuses exposed to clozapine during pregnancy,
a summary paper showed five cases of congenital malformations
in 61 children (8.2%) (Dev and Krupp, 1995). A Novartis
follow-up identified 22 fetal congenital malformations in 523
(4.2%) mothers treated with clozapine (McKenna et al., 2005).
In a cohort study, women taking clozapine and/or olanzapine
showed an increased risk for macrocephaly (Bodén et al., 2012).
Moreover, a case series reported seven spontaneous abortions in
84 women exposed to clozapine (Bazire, 2005). Some case reports
have described shoulder dystocia (Waldman and Safferman,
1993; Dickson and Hogg, 1998), atrial septum defect (Vavrusova
and Konikova, 1998), and ectopic anus (Reis and Källén, 2008).
Regarding the risk to infants, floppy infant syndrome (DiMichele
et al., 1996) and a decrease in heart rate variability (Yogev
et al., 2002; Coston et al., 2012; Guyon et al., 2015), seizure
(Stoner et al., 1997), gastroesophageal problems, and delayed
peristalsis (Karakula et al., 2004) have been observed. Concerning
the clinical outcome associated with clozapine exposure during
breastfeeding, data are even more scarce. One study reported
delayed speech acquisition in an infant exposed to clozapine
during 1 year of lactation (Mendhekar, 2007); an episode
of agranulocytosis and a case of drowsiness were observed
in another four cases (Dev and Krupp, 1995). Five cases of
in-utero and lactation exposure to clozapine reported fewer sleep
disturbances compared to those not exposed (Shao et al., 2015).
Finally, there are few data on the long-term outcome of children
exposed to clozapine during pregnancy. A case-control study
showed a lower adaptive behavior (Bayley-III) score in children
exposed to clozapine vs. other atypical antipsychotics (Shao
et al., 2015). Lastly, a case report observed the retardation of
psychomotor development in a child after 6 years of follow-up
(Tenyi and Trixler, 1998).
The heterogeneity of studies and clinical outcomes based
on distinct clozapine daily doses, different timing of exposures
during pregnancy and lactation, and the usage of concomitant
drugs in some cases leaves many questions unanswered (Mehta
and Van Lieshout, 2017). It has been suggested that the
accumulation of clozapine in fetal serum may be associated
with an increased rate of neonatal complications (Dev and
Krupp, 1995). There are currently two cases in the literature
reporting neonatal clozapine blood concentrations. In the first,
Barnas et al. (1994) suggested transplacental passage and relative
accumulation of clozapine in the neonate. The same trend for
clozapine accumulation was observed in breastmilk. The second
case (Moreno-Bruna et al., 2012) described a newborn with
delayed peristalsis on the second day of life, with an increase in
half-life elimination of the drug suggesting a substantial newborn
plasma clozapine concentration on the fifth and eighth day of
life.
Given the current increase in the prescription of atypical
antipsychotics, such as clozapine, in young psychotic
women (Toh et al., 2013), it seems important to know
better their pharmacokinetics and adverse effects during
pregnancy and lactation as well as its risk profile for neonatal
outcome.
METHODS
We report four cases of three Caucasian women who attended
the outpatient Perinatal Psychiatry Program of a teaching
hospital during pregnancy and postpartum with clozapine.
Complementary to their obstetric and psychiatric care, clozapine
and norclozapine plasma concentrations were determined in the
mother–infant pair on the day of delivery [intrapartum maternal
blood (IMB), fetal umbilical cord blood (UCB), and amniotic
fluid (AF)] to calculate the infant–maternal plasma clozapine
concentration ratio. The neonatal plasma concentration of
clozapine was measured several times after delivery to observe
half-life elimination in those neonates with artificial lactation
(Food and Drug Administration, 2005). Only in one case it was
possible to study the plasma concentrations of clozapine in both
the mother and the neonate at 33 h postpartum to calculate
the lactation transfer. Obstetric and pediatric outcomes were
reviewed from medical records. Pharmacological treatment was
administered with the consent of the patients. All patients gave
written informed consent for the presentation of their data.
The drug was analyzed in venous blood samples drawn in
the morning before a first daily dose of clozapine, and under
steady-state conditions. The blood samples were allowed to clot
at room temperature for 15–30min, and then centrifuged at 1800
× g/10min. Plasma was stored at −20◦C until analysis. Plasma
concentrations of clozapine/norclozapine, were measured using
a validated high-performance liquid chromatography method,
with UV diode array detection and solid- phase extraction
(Gupta, 1995; Liu et al., 2001). For amniotic fluid, drugs
were extracted using a double-step liquid–liquid procedure
(Titier et al., 2003). The within- and between-day precision
expressed as the coefficient of variation (CV) % were both
<10%. The limit of quantification (LOQ) was 5 ng/mL. Assuming
linear pharmacokinetic behavior, the elimination half-life (t1/2)
was calculated by means of 0.693/ke. The elimination rate
constant (ke) was determined from the neonate venous blood
clozapine concentration data vs. time after birth by linear least
squares regression analysis of the terminal portion of the log
concentration-time curve. Drug urine screening and cotinine
quantification were performed by immunoassay.
The aim of the present case-report series was to provide
new information on the features of clozapine pharmacokinetics
that determine its placental and lactation passage, as well as the
neonatal clozapine elimination half-life (t1/2) and neonatal and
infant/child outcomes.
Case Series
The first patient (M1) was a 37-year-old woman with paranoid
schizophrenia since the age of 24. She was treated with
risperidone 5 mg/day. Due to an episode of amenorrhea with
galactorrhea, risperidone was replaced by quetiapine 300mg/day.
At 34 years of age, she required hospital admission for a new
psychotic episode (Table 1). Clozapine was initiated and titrated
up to 550 mg/day with partial remission. Thirty sessions of
ECT were administered, and long-acting intramuscular (LAI)
risperidone was added (50 mg/14 days). After 3 years in stable
remission, she expressed the wish to have a child and her
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TABLE 1 | Maternal characteristics and pregnancy-related outcomes in the case series and in the previous cases reported in the literature.






















Psychiatric diagnosis CLZ- R
Schizophrenia
Schizoaffective Schizoaffective Schizophrenia Schizophrenia Schizophrenia Self-
intoxication
Concurrent diagnosis No No SUD No No Self-intoxication No
Age (years)* 37 34 33 34 31 27 34 16
Ethnicity Caucasian Caucasian Caucasian NA NA NA NA
Educational level High School High School High School NA NA NA NA
Marital status Married Married Living
together
NA NA Married NA
Employment status Employed Employed Unemployed NA NA NA NA






Planned Planned NA NA
Parity Primiparous Primiparous Primiparous Multiparous NA Multiparous NA NA
BMI (pre-pregnancy)—Kg/m2 31.84 27.78 24.90 28.09 NA NA 25.00 NA
Pregestational diabetes No No No No NA NA No NA
Family history of diabetes No Yes No No NA NA NA NA
PREGNANCY VARIABLES
Weight gain in pregnancy—Kg 13 16 11.5 11.7 25 NA 16.00 NA
Gestational diabetes No Yes at 14 gwk No No NA No No No
Other complications No No IUGR-1 at
28 g wk
No NA No No No
Type of delivery Vaginal Cesarean† Cesarean‡ Cesarean¶ Vaginal** Vaginal Vaginal Cesarean†
Maternal duration of gestation†† 38+6 40+5 38+6 39 41+0 39+0 40+0 32+0
BMI: body mass index; CLZ-R Schizophrenia: clozapine-resistant schizophrenia; GWK: gestational week; IUGR: intrauterine growth retardation; SUD: substance use disorder.
*Age at the time of pregnancy;
†
Emergency cesarean section; ‡Elective cesarean section due to breech presentation; ¶ Elective cesarean section for short interpregnancy period;
**Instrumental vaginal;
††
Maternal duration of gestation: weeks + days after last menstrual date.
intrauterine device (IUD) was removed. She was a primipara,
with a body mass index of 31.84, and no other medical
problems. When pregnancy was confirmed she was taking
clozapine 550 mg/day and LAI risperidone 50 mg/month and
she was smoking 18 cigarettes/day. She subsequently reduced
the number of cigarettes/day by 50%, and clozapine was
progressively titrated down to 350 mg/day; the LAI risperidone
dose was maintained. No agranulocytosis was detected. Four
ultrasounds during gestation showed physiological fetal well-
being parameters (Table 1). A spontaneous vaginal delivery
was carried out in the 38th week of pregnancy, with no
perinatal complications. No agranulocytosis, seizures, or other
neonatal complications were observed (Table 2). The plasma
concentrations of clozapine/ norclozapine in IMB, UCB, and
AF ratios are displayed in Table 3. Figure 1 shows the half-life
neonatal elimination of clozapine. Artificial lactation was carried
out. No psychotic relapse was recorded. In the follow-up of
the child at 6 years of age, symptoms of attention deficits and
hyperactivity were present without any diagnostic criteria for
ADHD.
The second patient (M2), a 34-year-old woman, was
diagnosed with schizoaffective disorder at the age of 18. She
was treated initially with haloperidol 15 mg/day, and later
on with sertindole 16 mg/day. Because of severe hypotension
the treatment was changed to amisulpride 150 mg/day and
risperidone 6 mg/day. She remained in remission for several
years. At 30 years of age, she decided to plan a pregnancy.
Due to an increase in prolactin level the risperidone dose was
reduced to 4.5 mg/day. However, as the patient started being
symptomatic, the 6 mg/day dose was reinstated and the patient
became asymptomatic. After more than 3 years of follow-up
without becoming pregnant, she switched treatment to 200
mg/day clozapine and after 6 months she became pregnant and
she returned to our program (Table 1). In the 19th week of
pregnancy, clozapine treatment was titrated down progressively
to a dose of 100 mg/day to avoid fetal accumulation (Barnas
et al., 1994). She developed diabetes during pregnancy that
was successfully controlled with long-acting insulin at 6 U/day.
Ultrasound examinations detected fetal macrosomia in the 29th
week of gestation. No other physiological parameters were
altered. She gave birth in the 40th week pregnancy by cesarean
delivery. No perinatal complications were recorded and there was
a good obstetric outcome (Table 2). No agranulocytosis, seizures
or other neonatal complications were observed. Table 3 shows
the plasma concentrations of clozapine/norclozapine in IMB and
UCB. Mixed breastfeeding was conducted for 5 days. At 33 hours
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TABLE 2 | Neonatal, infant, and child outcomes in the case series and in the previous cases reported in the literature.






















Infant sex Male Female Male Female Female Male Male Female
Estimated gestational age 38+6 40+5 38+6 39 41+0 39+0 40+0 32+0
Apgar score (1/5/10min) 9/10/10 9/10/10 6/10/10 9/10/10 5/8/– 1/–/– 10/10/– –/5/–
Arterial cord pH 7.09 7.18 7.21 N/A 7.34 NA N/A 7.19








































NICU admission No No Yes No No NA No NA
Hospital stay (days) 4 3 4 4 N/A 20min 17 NA
Congenital anomaly No No Inguinal hernia
and cryptorchi
dism (left)
No No No No No
Cardiovascular No No No No No No No Abnormal fetal
CTG









Blood leukocytes UCB (x
109/L)
25.17 22.23 8.65‡ 12.49 NA NA Normal NA
Urine drug test¶ (1st day
PP)
NA NA BZD (+) NA NA Etanol (-) NA NA
Infant feeding Formula Mixed BF 5
days, then
formula











No No NA No No
Last observation 10 years 32 months 16 months 5 months 6 months 20min 2 years 6 days




Others: renal, thyroid, gastrointestinal, central nervous system; ‡At 2nd day postpartum; ¶Urine drug test included alcohol, cannabis, heroin, methadone,
cocaine, benzodiazepines.
after delivery, the infant/mother clozapine ratio had decreased
by 48.9%. However, 5 days after delivery, the mother was briefly
hospitalized due to a relapse ofmanic psychotic symptoms, which
responded rapidly to an increase in clozapine to 200 mg/day, and
breastfeeding was stopped. No neurodevelopmental disorders
were detected in the infant after 32 months follow-up.
The third case (M3-1), a 33-year-old woman, had a severe
schizoaffective disorder comorbid with SUD for 8 years. She
was treated with several antipsychotic treatments (risperidone 3
mg/day, LAI risperidone 50 mg/month, olanzapine 20 mg/day,
paliperidone 9 mg/day, and aripiprazol 15 mg/day) without
achieving clinical stability. Finally, treatment was switched to
clozapine 200mg daily. In 2014 she had one first trimester
spontaneous abortion. In 2015, when she knew that she was
pregnant again, she tried to stop antipsychotic medication at
week 16, but the reappearance of auditory hallucinations forced
her to reintroduce clozapine 200mg daily at week 21. However,
in week 26, due to psychotic decompensation, cocaine and
alcohol abuse, as well as domestic abuse, she was hospitalized
until the end of pregnancy and clozapine was increased up to
300 mg/day and diazepam 10 mg/day was added to achieve
clinical remission. Ultrasound examinations showed type I
intrauterine growth restriction in the 28th week of gestation.
She gave birth to a boy in the 38th week of pregnancy by
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TABLE 3 | Placental passage and neonatal half-life values of clozapine and metabolite in the case series and in the previous reported in the literature.
























Schizoaffective Schizoaffective Schizophrenia Schizophrenia Schizophrenia No
Co-ocurrent diagnosis No No SUD* No No No No
CLZ therapy duration wk 0-delivery wk 0-delivery wk0-16,
21-delivery














No No VAL, PROM
RIS, FX
No




Tobacco daily NA NA No NA
Urine drug test during pregnancy‡ (+) Cotinine Negative (+) Cotinine (+) Cotinine NA NA No NA
Maternal CLZ dose at delivery
(mg/day)
350 100 200 200 50 100 1000 2000
[CLZ] AT DELIVERY (ng/ml) ¶ **
Umbilical cord blood (UCB) 77 68 113 67 27 NA NA NA
Amniotic fluid (AF) 61 NA 67 NA 11.60 NA NA NA
Maternal plasma (MP) 198 122 194 148 14.10 NA NA NA
CLZ UCB/MP ratio (%) 38.88 55.70 58.24 45.27 191.48 NA NA NA
[NORCLZ] AT DELIVERY (ng/ml)
Umbilical cord blood (UCB) 56 26 42 32 NA NA NA NA
Amniotic fluid (AF) 39 NA 52 NA NA NA NA NA
Maternal plasma (MP) 200 79 114 149 NA NA NA NA
NorCLZ UCB/MP ratio (%) 28.00 32.91 36.84 21.47 NA NA NA NA
NEONATAL HALF-LIFE (HOURS)
CLZ 99 NA 71.42 106.61 NA NA NA NA
NorCLZ 161.16 NA 187.30 130.75 NA NA NA NA
CLZ, clozapine; CLZ-R, Schizophrenia, clozapine resistant schizophrenia; DZ, diazepam; FX, fluoxetine; LA-RIS, long acting risperidone; NA, not available; NorCLZ, norclozapine; PROM,
prometazine; Self-intox, self intoxication; SER, sertraline: VAL, valproate; wk, week.
*SUD, alcohol, nicotine, cannabis, or cocaine substance use disorder;
†
first 5 month of pregnancy;
‡
Urine drug test included alcohol, cannabis, heroin, metadone, cocaine,
benzodiazepines, and cotinine; ¶Postmortem (at 24 h), Blood (µg/ml): [CLZ] 7.3, [NorCLZ] 2.3, [CLZ-N-oxide] 0.5. Liver (µg/ml): [CLZ] 28.0, [NorCLZ] 17.1, [CLZ-N-oxide] 31.1.
Kidney (µg/ml): [CLZ] 10.1, [NorCLZ] 6.1, [CLZ-N-oxide] 5.8; **Qualitative urine analysis of CLZ in the mother: (+)3 days after CLZ intake, and in urine of the neonate: (+) 6 days after
maternal CLZ intake.
cesarean delivery due to breech presentation (Table 1). The
Apgar-min 1 score was 6 and neonatal resuscitation was
initiated in the delivery room. The Apgar-min 5 score was
10, and arterial cord PH was 7.21. It was also noted that
the baby had a left inguinal hernia and left cryptorchidism.
The urine drug test was positive for benzodiazepines. No
agranulocytosis, seizures, or other neonatal complications were
observed. Cerebral and cardiac ultrasounds were normal
(Table 2). The plasma concentrations of clozapine/norclozapine
in IMB, UCB ,and AF were also measured (Table 3). Figure 1
shows the neonatal half-life elimination of clozapine. In this
case, the infant was bottle fed, and was discharged from the
hospital with his mother’s family, awaiting surgery. Generalized
neurodevelopmental delay was observed at the follow-up at 18
months. The mother was transferred to a mental institution
4 days after delivery to continue her treatment and clinical
stabilization.
Three months after discharge, the same patient arrived in
the Psychiatry Emergency Unit after alterations in her behavior.
There was no evidence of a relapse in schizoaffective disorder.
However, she was 6-weeks pregnant. In this new pregnancy
(M3-2) she was hospitalized. Treatment was maintained with
clozapine 200 mg/day throughout pregnancy, and sertraline 100
mg/day was added in gestational week 35 until postpartum. She
gave birth to a girl in the 39th week of pregnancy by elective
cesarean section. The Apgar-min 1/5 score was 9/10. The serum
concentrations of clozapine/norclozapine in IMB and UCB
were measured (Table 3). Figure 1 shows the neonatal half-life
elimination of clozapine. Again, the neonate was bottle fed and
was discharged from the hospital with his mother’s family. No
agranulocytosis or neurodevelopmental disorders were detected
in the infant at the 6-month follow-up. The mother continued
asymptomatic with the same treatment and she now attends the
Mental Health Community Center.
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FIGURE 1 | Neonatal clozapine (A) and norclozapnie (B) plasma concentration time profile. M1, Mother case 1; M3-1, Mother case 3, first pregnancy; M3-2, Mother
case 3, second pregnancy.
DISCUSSION
In this report we present four cases of clozapine treatment during
pregnancy focusing on the pharmacokinetics of clozapine and
the maternal and neonatal outcomes. The placental passage of
clozapine was partial in all four cases and the mean (SD) half-life
value of clozapine in neonates who were exposed in utero was
92 (18) h. In the only case with maternal lactation we found no
evidence of clozapine accumulation in the first 33 neonatal hours
of life. One of the four pregnancies was complicated by diabetes
mellitus. We did not observe any acute toxicological effects in
three of the four neonates. The only neonate with respiratory
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problems was also exposed to maternal diazepam treatment.
However, these results must be taken with caution being a case
series with small sample size.
The current report indicates that placental passage of
clozapine/norclozapine is partial during delivery (Table 2). These
results contrast with those published previously by Barnas
et al. (1994), who observed clear accumulation of clozapine in
fetal serum. These differences in results could be explained by
different maternal and fetal factors. The case by Barnas et al.
(1994) was free of concomitant medication with no possible
pharmacokinetic interaction. Our second case, treated also only
with clozapine, showed a UCB/IMB ratio close to the mean
ratio of the four cases. Another maternal factor to be taken into
account is the fact that M1, M3-1, and M3-2 smoked during
pregnancy. Pharmacokinetic studies have demonstrated lower
clozapine /norclozapine concentrations in smokers compared to
non-smokers (Lowe and Ackman, 2010). However, there was
no information about smoking in Barnas’ case report. Lastly,
partial placental passage has been described in other atypical
antipsychotics such as olanzapine, risperidone, and quetiapine as
well as the first-generation antipsychotic haloperidol, suggesting
a common pharmacokinetic behavior (Newport et al., 2007).
The elimination half-life of drugs has been related to adverse
effects. Neonatal clozapine pharmacokinetics are thought to
differ from those in adults (Jann et al., 1993) because cytochromes
CYP450 3A4 and 1A2, which are responsible for demethylation
of clozapine to norclozapine (desmethyl-clozapine) in adults,
are present to a lesser extent in neonates (Myllynen et al.,
2009). Furthermore, norclozapine is eliminated by glomerular
filtration, which is known to be reduced in newborns (Smits
et al., 2013). In our series the mean maternal, amniotic
fluid and fetal concentrations of clozapine were higher than
the concentrations of norclozapine. The clozapine/norclozapine
concentrations were similar in amniotic fluid and fetal serum in
our series. In contrast, in Barnas’ case clozapine concentrations
were similar in maternal serum and amniotic fluid, and there
was a clear accumulation in fetal serum. In neonates we also
observed higher concentrations of clozapine than norclozapine.
The estimate of half-life elimination of clozapine by Moreno-
Bruna et al. (2012) was 72 h. They found a delay in peristalsis that
they hypothesized was related to the neonatal concentration of
clozapine (200 ng/mL), which was indirectly estimated from the
neonatal half-life elimination of clozapine. In our three neonates
we found a mean half-life of clozapine of 92 h, with a mean
plasma neonatal concentration of clozapine of 85(24) ng/mL in
the first 24 h of life (Figure 1). This was not associated with
any neonatal adverse effect. We must point out that our mean
plasma neonatal concentration of clozapine was lower than that
estimated by Moreno-Bruna et al. (2012). In the literature there
are two cases of neonatal delayed peristalsis after maternal acute
clozapine intoxication in late pregnancy in two women that
were not receiving regular clozapine treatment (Kłys et al., 2007;
Novikova et al., 2009). In the first case, the baby died after 3 h
and the woman was saved. Post-mortem clozapine/norclozapine
plasma levels were obtained. In the second, the baby developed
abdominal distension on the first day of life, and the mother had
a multisystemic failure and passed away after 3 days. Clozapine
and its metabolites were detected in the urine of the mother at 3
days and the child at 6 days.
With regard to the lactation passage to clozapine, previous
data (Barnas et al., 1994) suggested an accumulation in maternal
milk. We were able to study lactation passage in only one mother
(M2). The Food and Drug Administration (2005) suggests that
the infant plasma concentration is probably the most direct
measure of infant risk from a drug received from breast milk. In
this sense, we observed that the infant/maternal plasma clozapine
concentration ratio decreased close to 88% over time, from 0.557
(delivery day) to 0.065 (33 h post-delivery). In our case, the
concentration of clozapine in the infant’s plasma was∼6% of the
corresponding maternal plasma drug concentration at 2nd day
of life. Then, different to Barna’s case our result did not suggest
accumulation of clozapine and metabolite on the 2nd day of
breastfeeding.
Finally, clozapine had no acute toxicological effects such as
agranulocytosis or seizures, in the exposed neonates, regardless
of exposure to other medications. However, one of the
newborns was diagnosed with intrauterine growth retardation
in the 28th gestational week, as well as left inguinal hernia
and cryptorchidism at birth. Moreover, he presented with
generalized neurodevelopmental delay and the consequent need
for continuous intensive care. His mother had a history of past
and current drug abuse (M3-1) during pregnancy. Importantly,
the second baby born to this mother (M3-2) showed normal
neurodevelopment. In this case, the baby was not exposed to
maternal substance use other than tobacco. Regarding the long-
term clinical outcome, signs and symptoms of attention deficit
and hyperactivity disorder were observed (M1) after 6 years of
follow-up.
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